07:00 , Sep 17, 2001 |  BioCentury  |  Finance

Ebb & Flow

With U.S. markets abruptly shut last week, companies with milestone-driven news will have to wait until this week to see if the announcements had any effect on valuations. And questions remain as to whether fundamental...
07:00 , Sep 4, 2001 |  BioCentury  |  Finance

Ebb & Flow

"The use of fetal tissue in research has recently been the subject of active political debate." - SyStemix's IPO prospectus, Aug. 6, 1991 Just like stem cells, news stories often regenerate. Thus, despite the currently...
08:00 , Nov 6, 2000 |  BC Week In Review  |  Company News

Coley Pharmaceutical Group board of directors update

(Financing, B19) Coley Pharmaceutical Group, Wellesley, Mass.   Business: Cancer, Infectious diseases, Autoimmune/Inflammation   Appointed: Andreas Bremer, managing director at AP Asset Management AG  ...
07:00 , Jun 1, 2000 |  BC Extra  |  Financial News

Maxia raises $20.5 million

Maxia (San Diego, Calif.), which is developing its MX6 topical small molecule inducer of apoptosis to treat high and low grade cervical intraepithelial neoplasia, raised $20.5 million in a venture round consisting of stock and...
08:00 , Mar 17, 2000 |  BC Extra  |  Financial News

Ciphergen raises $28.6 million

Ciphergen (Palo Alto, Calif.) sold 10.4 million shares in a venture round including Atlas Venture; Morgan Stanley Ventures; Essex Ventures; AP Asset Management; Orbimed Advisors; Falcon Technology Partners; MDS Capital Corporation; and SR One. The...